Table 1. Characteristics of study population.
| Total | Patients with TDR* | Patients without TDR* | OR (95%CI)" | p-value | |
| Genotypic resistance tested patients (%) | 1,667 (100) | 198 (11.9) | 1,469 (88.1) | ||
| Type of seroconversion (%) | 0.491 | ||||
| Acute | 746 (44.8) | 84 (42.4) | 662 (45.1) | ||
| Documented | 921 (55.2) | 114 (57.6) | 807 (54.9) | ||
| CDC category at sca (%) | 0.131 | ||||
| A | 1,544 (92.6) | 181 (91.4) | 1,363 (92.8) | ||
| B | 94 (5.6) | 16 (8.1) | 78 (5.3) | ||
| C | 29 (1.7) | 1 (0.5) | 28 (1.9) | ||
| Sex | 2.06 (0.824–6.57) | 0.151 | |||
| Men (%) | 1,588 (95.3) | 193 (97.5) | 1,395 (95.0) | ||
| Women (%) | 78 (4.7) | 5 (2.5) | 73 (5.0%) | ||
| Median age at sc (IQR * ) | 33 (27–39) | 34 (26–39) | 33 (27–39) | 0.872 | |
| Subtype (n = 1,664) | 0.001 | ||||
| B subtype (%) | 1,536 (92.3) | 195 (99.0) | 1,341 (91.4) | ||
| Non-B subtype (%) | 128 (7.7) | 2 (1.0) | 126 (8.6) | ||
| Transmission group (%) | |||||
| MSM° | 1,465 (87.9) | 182 (91.9) | 1,283 (87.3) | 1.65 (0.96–3.01) | 0.061 |
| Heterosexual contacts | 110 (6.6) | 8 (4) | 102 (7) | 0.56 (0.53–1.18) | 0.161 |
| Exposure at work | 5 (0.3) | 0 | 5 (0,3) | 1.01 | |
| High prevalence country | 30 (1.8) | 0 | 30 (2) | 0.041 | |
| Intravenous drug use | 21 (1.2) | 1 (0.5) | 20 (1.4) | 0.37 (0.01–2.32) | 0.51 |
| Unknown | 20 (1.2) | 4 (2) | 16 (1.1) | 1.87 (0.45–5.88) | 0.291 |
| Median VL at sc (log/ml) (IQR*) (n) | 5.25 (4.5–5.9) (785) | 5.2 (4.5–6.2) (82) | 5.26 (4.5–5.9) (669) | 0.672 | |
| Median CD4 cc ∼ at sca (cells/µl) (IQR*) (n) | 473 (350–642) (748) | 528 (374–647) (79) | 470 (348–641) (669) | 0.482 | |
| Median duration of FL-ART × (day) (CI) (n) | 810 (571–974) (922) | 477 (320–974) (122) | 823 (595–1182) (800) | 0.0453 | |
| Median time to FL-ART × (day) (CI) (n) | 1.011 (928–1.071) | 896 (736–1.156) | 1.014 (939–1.079) | 0.613 | |
| Median CD4 cc ∼ at FL-ART × start (cells/µl) (IQR*) (n) | 300.5 (213–408) (778) | 303 (204–406) (102) | 299.5 (214–422) (676) | 0.922 | |
| Median VL at FL-ART × start (log/ml) (IQR*) (n) | 5.00 (4.5–5.5) (795) | 5.11 (4.5–5.6) (108) | 5.00 (4.5–5.5) (687) | 0.52 |
asc: seroconversion.
1Fisher exact test.
2Mann-Whitney-U test.
3Log rank test.
°MSM: men who have sex with men].
*IQR: Interquartile range.
"CI: 95% confidence interval.
∼
cc: cell count.
×
FL-ART: first-line cART.